Cargando…
Comparative Outcomes of Budesonide MMX versus Prednisolone for Ulcerative Colitis: Results from a British Retrospective Multi-Centre Real-World Study
During the COVID-19 pandemic many IBD units chose Budesonide MMX (Cortiment) as the first-line treatment for flares of ulcerative colitis (UC) in outpatients for its favourable side effect profile. This retrospective study of all UC patients treated with oral steroids between 1 March 2019–30 June 20...
Autores principales: | Rosiou, Konstantina, Ong Ming San, Elaine, Kumar, Aditi, Esquivel, Kim, Almas, Saima, Stokes, Daniel, Ng, Tze, Jayasooriya, Nishani, Ranasinghe, Ian, Pollok, Richard, Brookes, Matthew, Selinger, Christian P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509767/ https://www.ncbi.nlm.nih.gov/pubmed/34640345 http://dx.doi.org/10.3390/jcm10194329 |
Ejemplares similares
-
Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
por: Maconi, Giovanni, et al.
Publicado: (2021) -
Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis
por: Lichtenstein, Gary R., et al.
Publicado: (2015) -
Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians
por: Rosiou, Konstantina, et al.
Publicado: (2021) -
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014) -
Obstetric Considerations in Pregnant Women with Crohn’s Disease
por: Rosiou, Konstantina, et al.
Publicado: (2023)